The ubiquitin-proteasome system is inhibited by p53 protein expression in human ovarian cancer cells

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 82-90

  Hwang, In Young ^a   Baguley, Bruce C ^a   Ching, Lai Ming ^a   Gilchrist, Catherine A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

EGFPu; Ovarian cancer; P53; Proteasome activity; UPS function

Indexed keywords

PROTEASOME; PROTEIN P53; UBIQUITIN;

ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL STRESS; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; HOMEOSTASIS; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UBIQUITINATION; WILD TYPE;

AUTOPHAGY; CELL LINE, TUMOR; CLONING, MOLECULAR; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, REPORTER; HOMEOSTASIS; HUMANS; OVARIAN NEOPLASMS; PLASMIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UP-REGULATION;

EID: 77953001887     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.025     Document Type: Article

References (53)

1. Zwickl P., Voges D., Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philosophical Transactions of the Royal Society of London - Series B: Biological Sciences 1999, 354:1501-1511.
2. Baumeister W., Walz J., Zuhl F., Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998, 92:367-380.
3. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771.
4. McClellan A.J., Tam S., Kaganovich D., Frydman J. Protein quality control: chaperones culling corrupt conformations. Nature Cell Biology 2005, 7:736-741.
5. Schwartz A.L., Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annual Review of Pharmacology and Toxicology 2009, 49:73-96.
6. Devoy A., Soane T., Welchman R., Mayer R.J., Devoy A., Soane T., Welchman R., Mayer R.J. The ubiquitin-proteasome system and cancer. Essays in Biochemistry 2005, 41:187-203.
7. Bazzaro M., Lee M.K., Zoso A., Stirling W.L.H., Santillan A., Shih I.-M., Roden R.B.S. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Research 2006, 66:3754-3763.
8. Ramirez P.T., Landen C.N., Coleman R.L., Milam M.R., Levenback C., Johnston T.A., Gershenson D.M. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic Oncology 2008, 108:68-71.
9. Richardson P.G., Hideshima T., Anderson K.C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10:361-369.
10. Lassus H., Leminen A., Lundin J., Lehtovirta P., Butzow R. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecologic Oncology 2003, 91:504-512.
11. Bullock A.N., Fersht A.R. Rescuing the function of mutant p53. Nature Reviews 2001, 1:68-76.
12. Ishimaru D., Andrade L.R., Teixeira L.S., Quesado P.A., Maiolino L.M., Lopez P.M., Cordeiro Y., Costa L.T., Heckl W.M., Weissmuller G., Foguel D., Silva J.L. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 2003, 42:9022-9027.
13. Rigacci S., Bucciantini M., Relini A., Pesce A., Gliozzi A., Berti A., Stefani M. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophysical Journal 2008, 94:3635-3646.
14. Jana N.R., Zemskov E.A., Wang G.-h., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics 2001, 10:1049-1059.
15. Verhoef L.G.G.C., Lindsten K., Masucci M.G., Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Human Molecular Genetics 2002, 11:2689-2700.
16. Khan L.A., Bauer P.O., Miyazaki H., Lindenberg K.S., Landwehrmeyer B.G., Nukina N. Expanded polyglutamines impair synaptic transmission and ubiquitin-proteasome system in Caenorhabditis elegans. Journal of Neurochemistry 2006, 98:576-587.
17. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
18. Yanisch-Perron C., Vieira J., Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 1985, 33:103-119. (erratum appears in Gene. 1992 May 1; 114(1): 81-3; PMID: 1375182).
19. Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. European Journal of Cancer 1995, 31:230-237.
20. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., Whang-Peng J., Rogan A.M., Green W.R., Ozols R.F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Research 1983, 43:5379-5389.
21. Hamilton T.C., Young R.C., Ozols R.F. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Seminars in Oncology 1984, 11:285-298.
22. Fogh J., Trempe G. New human tumor cell lines. Human Tumor Cells In Vitro 1975, 115-159. Plenum press, New York. J. Fogh (Ed.).
23. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Research 1996, 56:2649-2654.
24. Ward C.L., Omura S., Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83:121-127.
25. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with imageJ. Biophotonics International 2004, 11:36-42.
26. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
27. Wanker E.E., Scherzinger E., Heiser V., Sittler A., Eickhoff H., Lehrach H. Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods in Enzymology 1999, 309:375-386.
28. Kisselev A.F., Goldberg A.L., Raymond J.D. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods in Enzymology 2005, Academic Press, pp. 364-378.
29. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Research 1992, 52:4196-4199.
30. O'Connor P., Jackman J., Bae I., Myers T., Fan S., Mutoh M., Scudiero D., Monks A., Sausville E., Weinstein J., Friend S., Fornace A., Kohn K. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Research 1997, 57:4285-4300.
31. D.M. Richardson, The role of transforming growth factor beta in epithelial ovarian cancer, Obstetrics and Gynaecology, University of Auckland, 2008 (pp. xxvii, 261 leaves).
32. Menendez-Benito V., Heessen S., Dantuma N.P., Raymond J.D. Monitoring of Ubiquitin - dependent proteolysis with green fluorescent protein substrates. Methods in Enzymology 2005, Academic Press, pp. 490-511.
33. Ferreira S.T., Vieira M.N.N., De Felice F.G. Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases. IUBMB Life 2007, 59:332-345.
34. Bennett E.J., Bence N.F., Jayakumar R., Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Molecular Cell 2005, 17:351-365.
35. Baglioni S., Casamenti F., Bucciantini M., Luheshi L.M., Taddei N., Chiti F., Dobson C.M., Stefani M. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. Journal of Neuroscience 2006, 26:8160-8167.
36. King F.W., Wawrzynow A., Hohfeld J., Zylicz M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO Journal 2001, 20:6297-6305.
37. Tripathi V., Ali A., Bhat R., Pati U. CHIP chaperones wild type p53 tumor suppressor protein. Journal of Biological Chemistry 2007, 282:28441-28454.
38. Zylicz M., King F.W., Wawrzynow A. Hsp70 interactions with the p53 tumour suppressor protein. EMBO Journal 2001, 20:4634-4638.
39. Muller P., Hrstka R., Coomber D., Lane D.P., Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27:3371-3383.
40. Sasaki M., Nie L., Maki C.G. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. Journal of Biological Chemistry 2007, 282:14626-14634.
41. Wawrzynow B., Zylicz A., Wallace M., Hupp T., Zylicz M. MDM2 chaperones the p53 tumor suppressor. Journal of Biological Chemistry 2007, 282:32603-32612.
42. Nie L., Sasaki M., Maki C.G. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. Journal of Biological Chemistry 2007, 282:14616-14625.
43. Nedelsky N.B., Todd P.K., Taylor J.P. Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2008, 1782:691-699.
44. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
45. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:8204-8209.
46. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
47. Crighton D., Wilkinson S., O'Prey J., Syed N., Smith P., Harrison P.R., Gasco M., Garrone O., Crook T., Ryan K.M. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126:121-134. (see comment).
48. Tasdemir E., Maiuri M.C., Galluzzi L., Vitale I., Djavaheri-Mergny M., D'Amelio M., Criollo A., Morselli E., Zhu C., Harper F., Nannmark U., Samara C., Pinton P., Vicencio J.M., Carnuccio R., Moll U.M., Madeo F., Paterlini-Brechot P., Rizzuto R., Szabadkai G., Pierron G., Blomgren K., Tavernarakis N., Codogno P., Cecconi F., Kroemer G. Regulation of autophagy by cytoplasmic p53. Nature Cell Biology 2008, 10:676-687.
49. Morselli E., Tasdemir E., Maiuri M.C., Galluzzi L., Kepp O., Criollo A., Vicencio J.M., Soussi T., Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008, 7:3056-3061.
50. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry 1996, 65:801-847.
51. Tsubuki S., Saito Y., Kawashima S. Purification and characterization of an endogenous inhibitor specific to the Z-Leu-Leu-Leu-MCA degrading activity in proteasome and its identification as heat-shock protein 90. FEBS Letters 1994, 344:229-233.
52. Conconi M., Szweda L.I., Levine R.L., Stadtman E.R., Friguet B. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Archives of Biochemistry and Biophysics 1996, 331:232-240.
53. Vaziri S.A.J., Grabowski D.R., Hill J., Rybicki L.R., Burk R., Bukowski R.M., Ganapathi M.K., Ganapathi R. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent. Anticancer Research 2009, 29:2961-2969.